Insulet (Nasdaq: PODD) today announced a new integration for its Omnipod 5 platform, building on its partnership with Dexcom (Nasdaq: DXCM) .
Our sister site, Drug Delivery Business News, reports today that Insulet announced the compatibility of its Omnipod 5 App for iPhone with Dexcom G7 continuous glucose monitor (CGM). The latest integration combines the benefits of the companies’ latest technologies, all conveniently controlled from an iPhone.
Insulet’s Omnipod 5 App for iPhone offers full control of Omnipod 5, including the ability to bolus, change a pod, adjust settings, access insights and more. Users can now download the new app with Dexcom G7 and G6 compatibility from the Apple App Store.
Get the full story at our sister site, Drug Delivery Business News.
